Frontiers in Clinical Drug Research: Hematology

Volume: 2

Indexed in: EBSCO.



US $
30

*(Excluding Mailing and Handling)



Monoclonal Antibodies in Lymphoma

Pp. 256-299 (44)

Esmeralda Chi-yuan Teo and Colin Phipps

Abstract

Monoclonal antibodies (moAbs) have changed the landscape of lymphoma therapy. The chimeric anti-CD20 antibody, rituximab was the first to show significant activity in B-cell lymphomas. Since its FDA approval in 1997, rituximab has become a standard of care whether in combination with chemotherapy, or as a single-agent in induction and maintenance regimens in B-cell lymphoma. The success with rituximab paved the way for a steady stream of anti-lymphoma moAb therapies. Ofatumumab and obinutuzumab are next generation anti-CD20 antibodies designed to improve the cytotoxic effect of rituximab and enhance tumor cell killing. The breath of receptors amenable to Moab targeting extends far beyond CD20 and this chapter will review the most clinically impactful moAbs that have emerged over the past decade.

Keywords:

Monoclonal antibodies, lymphoma, antibody-drug conjugates, rituximab.

Affiliation:

Department of Haematology, Singapore General Hospital, 20 College Road, Singapore 169856.